单次与分次立体定向放射外科治疗脑转移瘤的多中心分析
该多中心回顾性研究比较了单次立体定向放射外科(SF-SRS)与分次立体定向放射外科(HF-SRS)治疗脑转移瘤的临床结局。对于HF-SRS,BED10≥50的病灶1年局部控制率数值上更高。
要点
- SF-SRS与HF-SRS的1年局部控制率和放射性坏死发生率无显著差异。
- 仅病灶≤2 cm与放射性坏死风险降低独立相关(HR 0.21)。
- HF-SRS中BED10≥50者1年局部控制率数值上高于BED10<50者。
核心结论
- HF-SRS与SF-SRS在脑转移瘤的局部控制和放射性坏死方面无差异。
- HF-SRS采用BED10≥50可能改善局部控制。
研究设计与样本
- 多中心回顾性研究,纳入2013至2018年5个放疗中心的脑转移瘤患者。
- 采用Kaplan-Meier法估计局部控制和放射性坏死,Cox比例风险模型进行多因素分析,并使用倾向评分调整。
主要发现
- SF-SRS与HF-SRS的1年局部控制率分别为91%(95%CI 86-96%)和85%(95%CI 75-95%),P=0.26。
- SF-SRS与HF-SRS的1年放射性坏死发生率分别为10%(95%CI 5-15%)和7%(95%CI 0.1-14%),P=0.73。
- 病灶>2 cm时,SF-SRS与HF-SRS的1年局部控制率分别为97%(95%CI 84-100%)和64%(95%CI 43-85%),P=0.06。
- 多因素分析中,仅病灶≤2 cm与放射性坏死风险降低相关(HR 0.21;95%CI 0.07-0.58,P<0.01)。
- HF-SRS中,BED10≥50的病灶1年局部控制率为100%,BED10<50者为77%(95%CI 65-88%),P=0.09。
关键数值与推荐
- SF-SRS剂量标准化,HF-SRS剂量方案可变。
- 既往全脑放疗在SF-SRS组和HF-SRS组分别为33%(74个病灶)和34%(38个病灶),P=0.30。
- HF-SRS的剂量效应评估采用假设α/β=10的生物有效剂量(BED10)作为总剂量的替代指标。
临床怎么用
- 对于脑转移瘤,SF-SRS和HF-SRS均可作为选项,两者局部控制和放射性坏死风险相似。
- HF-SRS时考虑BED10≥50可能有助于改善局部控制。
- 病灶大小≤2 cm与放射性坏死风险降低相关,可用于风险分层。
局限性
- 回顾性研究设计。
- HF-SRS剂量方案存在异质性。
- 中位随访时间12个月。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Hypofractionated-SRS (HF-SRS) may allow for improved local control and a reduced risk of radiation necrosis compared to single-fraction-SRS (SF-SRS). However, data comparing these two treatment approaches are limited. The purpose of this study was to compare clinical outcomes between SF-SRS versus HF-SRS across our multi-center academic network. METHODS: Patients treated with SF-SRS or HF-SRS for brain metastasis from 2013 to 2018 across 5 radiation oncology centers were retrospectively reviewed. SF-SRS dosing was standardized, whereas HF-SRS dosing regimens were variable. The co-primary endpoints of local control and radiation necrosis were estimated using the Kaplan Meier method. Multivariate analysis using Cox proportional hazards modeling was performed to evaluate the impact of select independent variables on the outcomes of interest. Propensity score adjustments were used to reduce the effects confounding variables. To assess dose response for HF-SRS, Biologic Effective Dose (BED) assuming an α/β of 10 (BED10) was used as a surrogate for total dose. RESULTS: One-hundred and fifty six patients with 335 brain metastasis treated with SF-SRS (n = 222 lesions) or HF-SRS (n = 113 lesions) were included. Prior whole brain radiation was given in 33% (n = 74) and 34% (n = 38) of lesions treated with SF-SRS and HF-SRS, respectively (p = 0.30). After a median follow up time of 12 months in each cohort, the adjusted 1-year rate of local control and incidence of radiation necrosis was 91% (95% CI 86-96%) and 85% (95% CI 75-95%) (p = 0.26) and 10% (95% CI 5-15%) and 7% (95% CI 0.1-14%) (p = 0.73) for SF-SRS and HF-SRS, respectively. For lesions > 2 cm, the adjusted 1 year local control was 97% (95% CI 84-100%) for SF-SRS and 64% (95% CI 43-85%) for HF-SRS (p = 0.06). On multivariate analysis, SRS fractionation was not associated with local control and only size ≤2 cm was associated with a decreased risk of developing radiation necrosis (HR 0.21; 95% CI 0.07-0.58, p < 0.01). For HF-SRS, 1 year local control was 100% for lesions treated with a BED10 ≥ 50 compared to 77% (95% CI 65-88%) for lesions that received a BED10 < 50 (p = 0.09). CONCLUSIONS: In this comparison study of dose fractionation for the treatment of brain metastases, there was no difference in local control or radiation necrosis between HF-SRS and SF-SRS. For HF-SRS, a BED10 ≥ 50 may improve local control.
引用
- Remick JS, Kowalski E, Khairnar R, et al. A multi-center analysis of single-fraction versus hypofractionated stereotactic radiosurgery for the treatment of brain metastasis. Radiat Oncol. 2020. PMID: 32466775. doi:10.1186/s13014-020-01522-6
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。